Apellis Pharmaceuticals (APLS) Reports Publication of Ph. 2 Study Highlighting Efficacy /7 Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMD
Tweet Send to a Friend
Apellis Pharmaceuticals Inc., (NASDAQ: APLS) today announced details about its Phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
